IAVI Bioscience Research Lab

An AIDS vaccine research lab anchors a bioscience hub in the repurposed Brooklyn Army Terminal.

Investment

  • NMTC Amount: $17,150,000
  • Total Project Cost: $23,804,299

IMPACT

  • 60 FTE jobs
  • 86 construction jobs

Investor

Project Description

Founded in 1996, International AIDS Vaccine Initiative (IAVI) is a global not-for-profit, public-private partnership working to accelerate the development of a vaccine to prevent HIV infection and AIDS. The City of New York’s ‘BioBAT’ initiative envisions developing a portion of the vast, WW II-era Brooklyn Army Terminal into a bioscience research hub, encouraging the incubation of a growing biotechnology sector in New York City. The New York City Economic Development Corporation identified IAVI as a potential anchor tenant that would attract other research facilities to the location. A broad coalition of project partners worked to design, develop and finance the tenant improvement of 39,000 sq. ft. of space in the Brooklyn Army Terminal for IAVI’s new research lab. Completed in 2008, IAVI’s new facility incorporates offices, conference rooms, research labs and support areas. The addition of IAVI has created jobs and educational opportunities in New York City’s burgeoning bioscience sector and worked towards fulfilling the City’s BioBAT initiative goals.

MAP

Address: 140 58th Street, Brooklyn, NY 11220

Census Tract: 36047001800

PDF Profile

Other New York Projects

NMTC financing supported a hub for education, training, and community health center on Buffalo’s West Side.
RDP allocated $10M in NMTCs to help Alstom expand their specialized manufacturing equipment line to rural America, and continue investing in Hornell (NY) as a key long-term U.S.
A non-profit healthcare provider expands services with medical offices, pharmacy and senior housing.

Financing for the owner of a Fine Fare Supermarkets in Brooklyn to purchase the building she had leased for 13 years. The purchase will stabilize occupancy costs, secure a long-term